China's IVD market maintains a strong momentum driven by the country's large population, aging society and people's increasing healthcare expenditure. Imported products remain robust in upstream and high-end market. From 2019 to 2022, U.S. exports to China have reported steadfast growth in major categories, such as blood products (HS3002), reagents (HS3822), medical and surgical devices (HS9018) and analytical devices (HS9027).
This webinar will provide you with valuable insights into the latest trends, opportunities, and challenges in this dynamic industry. We've assembled a panel of insiders who will share their knowledge and expertise on key aspects. You'll gain a deep understanding of the regulatory landscape and market entry strategies.
China In Vitro Diagnostic
6 Dec, 2023
11:00 a.m., EST
Santiago Ramos Bordajandi
Conrad W. Wong
Perspectives on the IVD Market in China
NMPA Regulatory Requirements and Registration Pathway
8 Tips to Succeed in China IVD Business
IP Protection in China
CACLP 2024 Introduction
Everett Wakai: U.S. Embassy Beijing
Jia Luo: Director of Product Planning, Vice Chairman Unit of China Association of In-Vitro Diagnostics
Grace Fu: Founder and CEO of China Med Device, LLC
Santiago Ramos Bordajandi: Managing Director & Senior Consultant of AI&C Limited
Conrad W. Wong: Senior Attorney of U.S. Patent and Trademark Office China
Karen DAI: Executive Deputy Secretary of China Association of In-Vitro Diagnostics, General Manager of GL events Ruihe (Shanghai) Exhibition Co., Ltd.
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.